Terms: = Lymphoma AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E
1330 results:
1. Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Mata JR; Zahurak M; Rosen N; DeZern AE; Jones RJ; Ambinder AJ
Transplant Cell Ther; 2024 Jun; 30(6):588-596. PubMed ID: 38521411
[TBL] [Abstract] [Full Text] [Related]
2. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract] [Full Text] [Related]
3. A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant.
Ohashi T; Kunimoto H; Nukui J; Teshigawara H; Koyama S; Miyazaki T; Hagihara M; Matsumoto K; Koshimizu E; Tsuchida N; Hamanoue H; Miyatake S; Yachie A; Matsumoto N; Nakajima H
Int J Hematol; 2024 May; 119(5):603-607. PubMed ID: 38489090
[TBL] [Abstract] [Full Text] [Related]
4. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
5. A case of peripheral T-cell lymphoma in which therapy-related myelodysplastic syndrome developed and a second autologous transplantation was performed.
Nakagawa SI; Nukii Y; Mochizuki K; Uchiyama A; Maeda Y; Kurokawa T
J Clin Exp Hematop; 2024 Mar; 64(1):59-64. PubMed ID: 38417872
[TBL] [Abstract] [Full Text] [Related]
6. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Pasvolsky O; Saliba RM; Popat UR; Alousi A; Mehta R; Yeh J; Al-Atrash G; Adeel M; Ramdial J; Marin D; Rondon G; Kebriaei P; Champlin R; Daver N; Dinardo C; Short NJ; Shpall EJ; Oran B
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e196-e204. PubMed ID: 38403505
[TBL] [Abstract] [Full Text] [Related]
7. [Bone marrow histology of cytopenias : Contribution to hematological differential diagnosis].
Kreipe H
Pathologie (Heidelb); 2024 Mar; 45(2):148-158. PubMed ID: 38381371
[TBL] [Abstract] [Full Text] [Related]
8. Hematopoietic cell transplantation (HCT) in mds patients of older age.
Niederwieser C; Kröger N
Leuk Lymphoma; 2024 May; 65(5):570-584. PubMed ID: 38315612
[TBL] [Abstract] [Full Text] [Related]
9. Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR-ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases.
Nowak J; Witkowska A; Rogatko-Koroś M; Malinowska A; Graczyk-Pol E; Nestorowicz-Kałużna K; Flaga A; Szlendak U; Wnorowska A; Gawron A
HLA; 2024 Feb; 103(2):e15364. PubMed ID: 38312022
[TBL] [Abstract] [Full Text] [Related]
10. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roué G; Valcárcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellström-Lindberg E; Solé F; Esteller M
Cancer Res Commun; 2024 Feb; 4(2):365-377. PubMed ID: 38300528
[TBL] [Abstract] [Full Text] [Related]
11. Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Stein EM; Fathi AT; Harb WA; Colak G; Fusco A; Mangan JK
Leuk Lymphoma; 2024 Apr; 65(4):503-510. PubMed ID: 38259250
[TBL] [Abstract] [Full Text] [Related]
12. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Rajakumaraswamy N; Gandhi M; Wei AH; Sallman DA; Daver NG; Mo S; Iqbal S; Karalliyadda R; Chen M; Wang Y; Vyas P
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):260-268.e2. PubMed ID: 38216397
[TBL] [Abstract] [Full Text] [Related]
13. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Nabergoj M; Eikema DJ; Koster L; Platzbecker U; Sockel K; Finke J; Kröger N; Forcade E; Nagler A; Eder M; Tischer J; Broers AEC; Kuball J; Wilson KMO; Hunault-Berger M; Collin M; Russo D; Corral LL; Helbig G; Mussetti A; Scheid C; Gurnari C; Raj K; Drozd-Sokolowska J; Yakoub-Agha I; Robin M; McLornan DP
Bone Marrow Transplant; 2024 Mar; 59(3):395-402. PubMed ID: 38195984
[TBL] [Abstract] [Full Text] [Related]
14. Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey.
Mo A; Weinkove R; Wood EM; Shortt J; Johnston A; McQuilten ZK;
Eur J Haematol; 2024 Apr; 112(4):621-626. PubMed ID: 38123137
[TBL] [Abstract] [Full Text] [Related]
15. When to use which molecular prognostic scoring system in the management of patients with mds?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract] [Full Text] [Related]
16. Effect of Conditioning Regimens and Graft-versus-Host Disease Prophylaxis on the Outcomes of Umbilical Cord Blood Transplantation Performed with Cyclophosphamide/Total Body Irradiation-Based Regimens.
Imahashi N; Kurita N; Konuma T; Takahashi S; Nishida T; Tanaka M; Nakamae H; Kawakita T; Ota S; Doki N; Onishi Y; Sawa M; Ozeki K; Hiramoto N; Onizuka M; Ishimaru F; Ichinohe T; Atsuta Y; Kanda J
Transplant Cell Ther; 2024 Mar; 30(3):318.e1-318.e11. PubMed ID: 38081416
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
Zeidan AM; Mearns ES; Ng CD; Shah A; Lamarre N; Yellow-Duke A; Alrawashdh N; Yang B; Cheng WH; Bui CN; Svensson A
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):177-186. PubMed ID: 37996264
[TBL] [Abstract] [Full Text] [Related]
18. T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
Schoelinck J; Gervasoni J; Guillermin Y; Beillard E; Pissaloux D; Chassagne-Clement C
Virchows Arch; 2024 May; 484(5):853-857. PubMed ID: 37985498
[TBL] [Abstract] [Full Text] [Related]
19. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Parrondo RD; Iqbal M; Von Roemeling R; Von Roemeling C; Tun HW
Front Immunol; 2023; 14():1239082. PubMed ID: 37954584
[TBL] [Abstract] [Full Text] [Related]
20. CDC-NET: a cell detection and confirmation network of bone marrow aspirate images for the aided diagnosis of AML.
Su J; Liu Y; Zhang J; Han J; Song J
Med Biol Eng Comput; 2024 Feb; 62(2):575-589. PubMed ID: 37953336
[TBL] [Abstract] [Full Text] [Related]
[Next]
